Capricor Therapeutics, Inc. (CAPR) Earnings History
Net Loss27 years of earnings data (1999–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Capricor Therapeutics, Inc. (CAPR) Earnings Overview
As of June 23, 2026, Capricor Therapeutics, Inc. (CAPR) reported trailing twelve-month net income of -$115M, reflecting -96.5% year-over-year growth. The company earned $-2.00 per diluted share over the past four quarters.
Looking at the long-term picture, CAPR's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2017.
Capricor Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($65M net income, -32.5% margin), CRSP (-$569M net income, -16569.8% margin), EXEL ($833M net income, 33.7% margin), CAPR has comparable earnings metrics. Compare CAPR vs SRPT →
CAPR Earnings vs Peers
Earnings metrics vs comparable public companies
CAPR Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$105M | -159.6% | -$108M | $-2.26 | - | - |
| 2024 | -$40M | -81.6% | -$43M | $-1.15 | -181.7% | -191.1% |
| 2023 | -$22M | +23.2% | -$24M | $-0.83 | -88.5% | -95.6% |
| 2022 | -$29M | -44.9% | -$30M | $-1.18 | -1137.4% | -1163.9% |
| 2021 | -$20M | -46.6% | -$21M | $-0.87 | -8175.9% | -8549.9% |
| 2020 | -$14M | -78.7% | -$14M | $-0.88 | -4401.9% | -4412.6% |
| 2019 | -$8M | +49.7% | -$8M | $-2.06 | -760.4% | -769.5% |
| 2018 | -$15M | -724.9% | -$15M | $-5.17 | -909.1% | -917.2% |
| 2017 | $2M | +112.9% | -$13M | $0.90 | 91.2% | -482.4% |
| 2016 | -$19M | -46.3% | -$17M | $-10.14 | -589.6% | -532.2% |
| 2015 | -$13M | -106.8% | -$13M | $-8.09 | -340.5% | -334.0% |
| 2014 | -$6M | +30.1% | -$6M | $-5.31 | -149.2% | -144.4% |
| 2013 | -$9M | -369.7% | -$7M | $-8.47 | -1767.0% | -1371.7% |
| 2012 | -$2M | +61.2% | -$2M | $-2.10 | -968.3% | -1248.1% |
| 2011 | -$5M | +19.0% | -$5M | $-65.43 | -360.5% | -361.5% |
| 2010 | -$6M | +23.4% | -$6M | $-93.75 | - | - |
| 2009 | -$8M | +40.1% | -$7.88B | $-154.56 | - | - |
| 2008 | -$13M | -27.5% | -$13.40B | $-272.15 | - | - |
| 2007 | -$10M | -299.0% | -$10M | $-304.06 | -10160.7% | -9368.8% |
| 2006 | -$3M | -13589.5% | -$2M | $-95.00 | -678.0% | -656.0% |
| 2005 | $-18,861 | -4.3% | $-18,861 | $-12.49 | - | - |
| 2004 | $-18,077 | -11.9% | $-18,977 | $-11.97 | - | - |
| 2003 | $-16,157 | -3.7% | $-16,157 | $-10.70 | -739.8% | -739.8% |
| 2002 | $-15,587 | +30.1% | $-17,779 | $-10.32 | -135.7% | -154.8% |
| 2001 | $-22,303 | +38.9% | $-22,303 | $-14.77 | - | - |
| 2000 | $-36,522 | -18161.0% | $-36,522 | $-26.56 | - | - |
| 1999 | $-200 | - | $-200 | $0.00 | - | - |
Download Data
Export CAPR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CAPR — Frequently Asked Questions
Quick answers to the most common questions about buying CAPR stock.
What is CAPR earnings per share (EPS)?
CAPR trailing twelve-month (TTM) diluted EPS is $-2.00, reflecting -96.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Capricor Therapeutics, Inc.'s net income?
Capricor Therapeutics, Inc. (CAPR) trailing twelve-month net income is $-115M as of 2025. Earnings declined -96.5% year-over-year.
Is CAPR profitable?
CAPR is not currently profitable on a TTM basis, reporting a net loss of $-115M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CAPR's earnings growth rate?
CAPR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are CAPR's profit margins?
Capricor Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -46.6%.
Is CAPR growing earnings?
CAPR earnings are declining — EPS fell -96.5% year-over-year. TTM net income dropped to $-115M. This contrasts with the 5-year CAGR of N/A.
What was CAPR's best earnings year?
Capricor Therapeutics, Inc.'s highest annual net income on record is $2M, achieved in fiscal year 2017. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were CAPR's earnings last quarter?
CAPR's most recent reported quarter was Q1 2026. Net income was $-34M with diluted EPS of $-0.59. For a full breakdown of all quarters, see the quarterly earnings table on this page.